Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Incyte Corporation's new CEO, William Meury, outlined the company's strategic vision at the Wells Fargo conference, emphasizing a robust pipeline to drive durable revenue growth beyond the upcoming Jakafi LOE. A core focus is the myeloproliferative neoplasm (MPN) pipeline, particularly the mCALR inhibitor 989, which showed promising essential thrombocythemia (ET) data, with pivotal trials planned for early 2026 and myelofibrosis (MF) data expected by year-end, targeting a $7.5 billion market opportunity. The company also highlighted strong performance in its immunology and inflammation (I&I) franchise, projecting double-digit growth for Opzelura and anticipating Povorcitinib's NDA submission for hidradenitis suppurativa (HS) in early 2026, addressing a potential $5-6 billion market. Incyte further provided updates on its oncology pipeline, including competitive G12D and TGF-beta by PD-1 bispecific programs, underscoring a disciplined approach to expand its specialized therapeutic areas.

Analysis

In a detailed strategic overview, Incyte's new CEO, William Meury, articulated a clear plan to navigate the upcoming Jakafi loss of exclusivity (LOE) by investing in a multi-pillar pipeline. The core strategy is to transition the myeloproliferative neoplasm (MPN) market from Jakafi to a new standard of care built on a portfolio of five targeted therapies. The lead asset, 989 (an mCALR inhibitor), is the most immediate value driver, with encouraging essential thrombocythemia (ET) data presented and pivotal trials planned for early 2026. Critical myelofibrosis (MF) data for 989 is expected by year-end, which will inform its development in a market segment the company sizes at a $7.5 billion total addressable opportunity for CALR-mutant patients. The Jakafi XR launch in mid-2026 is positioned as a tool to create a residual revenue stream, with a sober 20% conversion estimate, but the company's valuation hinges on the next-generation pipeline. Beyond hematology, the immunology franchise provides a solid secondary growth engine. Opzelura is described as a double-digit growth asset, projected to potentially double in size by 2030, while Povorcitinib is poised for an NDA submission in hidradenitis suppurativa (HS) in early 2026, targeting a market estimated at $5-6 billion. The oncology pipeline, with upcoming ESMO data for its G12D and TGF-beta programs, represents further optionality, reflecting a disciplined but opportunistic approach to business development.

Key Decisions for Investors

• Investors should closely monitor the year-end data release for the mCALR inhibitor 989 in myelofibrosis, as positive results in both monotherapy and combination settings would be a major de-risking event for Incyte's post-Jakafi growth narrative.
• Evaluate the company's ability to execute its 'invest and launch' strategy through the Jakafi LOE, focusing on the potential for its five-asset MPN pipeline to supplant the current standard of care, which represents the primary long-term value driver.
• Consider the immunology franchise, led by Opzelura's steady double-digit growth and povorcitinib's entry into the sizable hidradenitis suppurativa market, as a key source of revenue diversification and a buffer against potential setbacks in the core hematology pipeline.
• Treat the upcoming ESMO data for the G12D and TGF-beta oncology programs as significant upside catalysts; while this area is highly competitive, clinical success here could materially enhance the company's long-term growth profile and valuation.